9 Meters Biopharma, Inc. – NASDAQ:NMTR
9 Meters Biopharma stock price today
9 Meters Biopharma stock price monthly change
9 Meters Biopharma stock price quarterly change
9 Meters Biopharma stock price yearly change
9 Meters Biopharma key metrics
Market Cap | 1.04M |
Enterprise value | 4.63M |
P/E | -0.4 |
EV/Sales | N/A |
EV/EBITDA | -0.07 |
Price/Sales | N/A |
Price/Book | 7.15 |
PEG ratio | 0.03 |
EPS | -3.79 |
Revenue | N/A |
EBITDA | -42.77M |
Income | -49.80M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for free9 Meters Biopharma stock price history
9 Meters Biopharma stock forecast
9 Meters Biopharma financial statements
| Jun 2022 | 0 | -11.06M | |
|---|---|---|---|
| Sep 2022 | 0 | -9.99M | |
| Dec 2022 | 0 | -13.04M | |
| Mar 2023 | 0 | -15.70M |
| Jun 2022 | 31508478 | 9.42M | 29.91% |
|---|---|---|---|
| Sep 2022 | 42135208 | 28.67M | 68.05% |
| Dec 2022 | 33147844 | 30.74M | 92.76% |
| Mar 2023 | 9313037 | 15.61M | 167.64% |
| Jun 2022 | -7.78M | 0 | 0 |
|---|---|---|---|
| Sep 2022 | -9.96M | 0 | 19.91M |
| Dec 2022 | -9.73M | -2.84K | -2.17M |
| Mar 2023 | -9.74M | 0 | -12.28M |
9 Meters Biopharma alternative data
| Aug 2023 | 10 |
|---|---|
| Sep 2023 | 10 |
| Oct 2023 | 10 |
| Nov 2023 | 10 |
| Dec 2023 | 10 |
| Jan 2024 | 10 |
| Feb 2024 | 10 |
| Mar 2024 | 10 |
| Apr 2024 | 10 |
| May 2024 | 10 |
| Jun 2024 | 10 |
| Jul 2024 | 10 |
9 Meters Biopharma other data
| Period | Buy | Sel |
|---|---|---|
| May 2022 | 172383 | 0 |
| Jul 2022 | 300000 | 0 |
| Apr 2023 | 0 | 9100 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | SENSENIG BETHANY officer: Chief Financial Officer | Common stock | 9,100 | $1.21 | $11,011 | ||
Purchase | TEMPERATO JOHN director, officer.. | Common stock | 125,000 | $0.23 | $28,500 | ||
Purchase | SIRGO MARK A director | Common stock | 175,000 | $0.25 | $43,050 | ||
Purchase | CONSTANTINO MICHAEL T. director | Common Stock | 16,000 | $0.48 | $7,616 | ||
Purchase | TEMPERATO JOHN director, officer.. | Common Stock | 50,000 | $0.45 | $22,300 | ||
Purchase | SIRGO MARK A director | Common Stock | 106,383 | $0.47 | $50,000 | ||
Purchase | SIRGO MARK A director | Common stock | 86,449 | $0.58 | $49,968 | ||
Purchase | TEMPERATO JOHN director, officer.. | Common stock | 100,000 | $0.56 | $55,600 | ||
Purchase | SIRGO MARK A director | Common Stock | 50,000 | $0.89 | $44,500 | ||
Purchase | SIRGO MARK A director | Common stock | 20,000 | $1.06 | $21,200 |
| Patent |
|---|
Application Filling date: 3 Aug 2021 Issue date: 25 Aug 2022 |
Application Filling date: 13 Apr 2020 Issue date: 12 May 2022 |
Grant Utility: Treatment of cancer with larazotide derivatives in combination with immune checkpoint inhibitors Filling date: 23 Apr 2021 Issue date: 22 Mar 2022 |
Application Filling date: 3 Nov 2021 Issue date: 17 Feb 2022 |
Application Filling date: 19 Mar 2019 Issue date: 25 Nov 2021 |
Application Filling date: 10 Jun 2021 Issue date: 30 Sep 2021 |
Application Filling date: 23 Apr 2021 Issue date: 5 Aug 2021 |
Grant Utility: Compositions and methods for treating disease associated with permeability of intestinal epithelium Filling date: 12 Feb 2018 Issue date: 13 Jul 2021 |
Application Filling date: 10 Feb 2021 Issue date: 10 Jun 2021 |
Application COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPERGLYCEMIA, INSULIN RESISTANCE, AND ASSOCIATED ORGAN DAMAGE Filling date: 8 Apr 2019 Issue date: 11 Mar 2021 |
| Insider | Compensation |
|---|---|
| Mr. John Temperato (1965) Pres, Chief Executive Officer & Director | $652,440 |
Dr. Patrick H. Griffin (1955) Chief Medical Officer | $500,550 |
Mr. Edward J. Sitar CPA, CPA (1963) Chief Financial Officer | $397,400 |
-
What's the price of 9 Meters Biopharma stock today?
One share of 9 Meters Biopharma stock can currently be purchased for approximately $0.09.
-
When is 9 Meters Biopharma's next earnings date?
Unfortunately, 9 Meters Biopharma's (NMTR) next earnings date is currently unknown.
-
Does 9 Meters Biopharma pay dividends?
No, 9 Meters Biopharma does not pay dividends.
-
How much money does 9 Meters Biopharma make?
9 Meters Biopharma has a market capitalization of 1.04M.
-
What is 9 Meters Biopharma's stock symbol?
9 Meters Biopharma, Inc. is traded on the NASDAQ under the ticker symbol "NMTR".
-
What is 9 Meters Biopharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of 9 Meters Biopharma?
Shares of 9 Meters Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 9 Meters Biopharma's key executives?
9 Meters Biopharma's management team includes the following people:
- Mr. John Temperato Pres, Chief Executive Officer & Director(age: 60, pay: $652,440)
- Dr. Patrick H. Griffin Chief Medical Officer(age: 70, pay: $500,550)
- Mr. Edward J. Sitar CPA, CPA Chief Financial Officer(age: 62, pay: $397,400)
-
How many employees does 9 Meters Biopharma have?
As Jul 2024, 9 Meters Biopharma employs 10 workers.
-
When 9 Meters Biopharma went public?
9 Meters Biopharma, Inc. is publicly traded company for more then 9 years since IPO on 11 Jul 2016.
-
What is 9 Meters Biopharma's official website?
The official website for 9 Meters Biopharma is 9meters.com.
-
Where are 9 Meters Biopharma's headquarters?
9 Meters Biopharma is headquartered at 8480 Honeycutt Road, Raleigh, NC.
-
How can i contact 9 Meters Biopharma?
9 Meters Biopharma's mailing address is 8480 Honeycutt Road, Raleigh, NC and company can be reached via phone at +91 92751933.
9 Meters Biopharma company profile:
9 Meters Biopharma, Inc.
9meters.comNASDAQ
10
Biotechnology
Healthcare
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Raleigh, NC 27615
CIK: 0001551986
ISIN: US6544052086
CUSIP: 654405109
